Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 32,914 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo-Control Clear all
Completed Phase 4 Interventional Results available

Determining the Prognostic Value of Continuous Intrathecal Infusion

NCT03523000
View directory record Official record
Conditions
Lumbar Post-Laminectomy Syndrome, Chronic Low Back Pain, Vertebral Compression Fracture, Failed Back Surgery Syndrome
Interventions
Continuous intrathecal prognostic infusion test, Bupivacaine, Fentanyl, Placebo, Intrathecal Drug Delivery System (IDDS)
Other · Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 21, 2026, 2:36 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

NCT01196936
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment
Drug · Procedure · Other + 1 more
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 21, 2026, 2:36 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

NCT00947011
View directory record Official record
Conditions
Glucose Homeostasis
Interventions
Placebo, Januvia
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Antihistamines on Pre-Pulse Inhibition

NCT01537471
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Meclizine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 21, 2026, 2:36 PM EDT
Not listed Phase 3 Interventional

Femoral Nerve Block Compared to Exparel in Total Knee Replacement

NCT02473198
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Exparel, Femoral Nerve Block Bupivacaine, Toradol, Morphine Sulfate
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
18 Years to 73 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 21, 2026, 2:36 PM EDT
Terminated Phase 4 Interventional Results available

Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?

NCT02181387
View directory record Official record
Conditions
Pain
Interventions
Acetaminophen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine, control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
5,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 21, 2026, 2:36 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

NCT06149793
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Empagliflozin, Placebo Control
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 4 Interventional

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

NCT00106821
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide Inhalation Powder
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Sepulveda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus

NCT00525421
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Curcuminoids, Placebo
Drug
Lead sponsor
Nita Chainani Wu
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Not applicable Interventional

Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis

NCT00004414
View directory record Official record
Conditions
Cholestasis
Interventions
sincalide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
Up to 30 Days
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
6
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 21, 2026, 2:36 PM EDT
Completed No phase listed Observational

Novel Therapy for Glucose Intolerance in HIV Disease

NCT02006914
View directory record Official record
Conditions
Insulin Resistance
Interventions
Chromium Picolinate
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

NCT00577577
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
rhIGF-I/rhIGFBP-3, placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
21 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 4 Interventional Results available

Benzocaine Gel Toothache Dose-Response Study

NCT00474175
View directory record Official record
Conditions
Toothache
Interventions
Placebo gel, benzocaine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
12 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

NCT03361865
View directory record Official record
Conditions
UC (Urothelial Cancer)
Interventions
Pembrolizumab, Epacadostat, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Tucson, Arizona • Orange, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 21, 2026, 2:36 PM EDT
Terminated Phase 2 Interventional Results available

Investigation of Corticosteroid Versus Placebo Injection in Patients With Syndesmotic Ligament Injury or High Ankle Sprain

NCT02892500
View directory record Official record
Conditions
Ankle Injuries
Interventions
bupivacaine hydrochloride and betamethasone sodium phosphate, bupivacaine hydrochloride
Drug
Lead sponsor
Sanford Health
Other
Eligibility
16 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 3 Interventional

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I

NCT00546507
View directory record Official record
Conditions
Osteoarthritis
Interventions
TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo
Drug · Other
Lead sponsor
Mika Pharma GmbH
Industry
Eligibility
40 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
43
States / cities
Huntsville, Alabama • Mobile, Alabama • Mesa, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 2 Interventional

A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia

NCT01277107
View directory record Official record
Conditions
Insomnia
Interventions
Zaleplon AP formulation, Placebo capsule
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 21, 2026, 2:36 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

NCT07142707
View directory record Official record
Conditions
Obesity
Interventions
MBX 4291, Placebo
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Doral, Florida • Lexington, Kentucky • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02246764
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
19 Years to 99 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 21, 2026, 2:36 PM EDT
Withdrawn Phase 4 Interventional

Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault

NCT03997864
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Prazosin, Placebos
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

NCT04178993
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 21, 2026, 2:36 PM EDT